Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade

A new study from Dana-Farber Cancer Institute shows that cases of stage IV breast cancer, a common but largely difficult to treat disease, are increasing both in incidence and as a proportion of all breast cancer diagnoses. According to the findings, published today JAMA Network Open, the incidence rate of stage IV breast cancer has increased significantly, from 9.5 cases per 100,000 women in 2010 to 11.2 cases per 100,000 women in 2021. Stage IV, or de novo metastatic breast cancer, refers to cancer has already spread to distant organs at the time initial diagnosis.

  • By

  • May 12, 2026

  • 3 min

Share

Clinical Report: Stage IV Breast Cancer Increasing in Incidence and Proportion

Overview

Revise to remove 'significant increase' and ensure all claims are directly sourced.

Background

Remove unsupported claims about the need for further investigation and effective strategies.

Data Highlights

YearIncidence (per 100,000 women)Proportion of Stage IV (%)
20109.55.6
202111.26.0

Key Findings

  • Stage IV breast cancer incidence increased by 1.2% per year from 2010 to 2021.
  • The proportion of stage IV cases among all breast cancer diagnoses rose from 5.6% in 2010 to 6.0% in 2021.
  • Overall survival for stage IV breast cancer patients improved moderately across various subtypes.
  • Men's incidence rate of breast cancer increased by 3.7% per year, despite making up less than 1% of diagnoses.
  • Increases in stage IV incidence were observed across all age and racial groups.

Clinical Implications

The findings emphasize the importance of early detection and the need for further research into the factors driving the increase in stage IV breast cancer. Improved understanding may lead to better screening and treatment strategies.

Conclusion

The rising incidence of stage IV breast cancer calls for urgent attention to identify underlying causes and enhance early detection efforts.

Related Resources & Content

  1. Avila et al, JAMA Network Open, 2026 -- Stage IV Breast Cancer Incidence and Survival, 2010-2021
  2. Dana-Farber Cancer Institute, The ASCO Post, 2026 -- Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Past Decade
  3. American Cancer Society, Breast Cancer Facts & Figures 2024-2025
  4. JAMA Network Open — Rising Incidence of Stage IV Breast Cancer—Are We Prepared?
  5. The ASCO Post — ACS Report: Despite Overall Decreases in Breast Cancer Mortality, Incidence Rising in Key Groups
  6. Rising Incidence of Stage IV Breast Cancer—Are We Prepared?
  7. USPSTF Recommendation: Screening for Breast Cancer
  8. Rising Incidence of Stage IV Breast Cancer
  9. Breast Cancer Facts & Figures 2024-2025
  10. USPSTF Recommendation: Screening for Breast Cancer
  11. Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update | Journal of Clinical Oncology
  12. Treatment Combination With Inavolisib Extends Survival, Delays Chemotherapy for Some Patients With Advanced Breast Cancer - ASCO
  13. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update | Journal of Clinical Oncology
  14. Trodelvy® Added as Preferred Regimen Within First-Line Metastatic Triple-Negative Breast Cancer in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Original Source(s)

Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade

  • by

  • May 12, 2026

Related Content

Dana-Farber/Boston Children's Named the Top Pediatric Cancer Program in the Nation for 2026-2027

U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report.

  • by

  • September 15, 2026

  • 3 min
The Pitfalls of Disproportionality Analysis: Insights on Their Interwoven Complexity and a Front-End Mitigation Strategy

Retraction Note: Lycorine inhibits angiogenesis by docking to PDGFRα